About: Cross-reaction of sera from COVID-19 patients with SARS-CoV assays.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cross-reaction of sera from COVID-19 patients with SARS-CoV assays. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cross-reaction of sera from COVID-19 patients with SARS-CoV assays.
Creator	Dche, Eng, Hong Frcpath, Lim, Seng, »more»
source	MedRxiv
abstract	Background: The SARS-CoV-2 shares 74.5% genome identity with SARS-CoV, both exhibiting a similar well conserved structure. Therefore, antibodies produced in COVID-19 and SARS patients should not be that dissimilar. We evaluated SARS-CoV test assays to detect for the presence of antibodies to SARS-CoV-2 and tried to determine the timing of appearance of these antibodies by testing serial sera from these patients. Methods: Tests were carried out using ELISA (total antibodies) and indirect immunofluorescence (IIFA) (IgM & IgG) methods on serial sera from patients confirmed with SARS-CoV-2 infection. Results: Cross-reactivity was seen in these two test assays with sera from COVID-19 patients and was detected in 6 out of 7 patients from 7 days after onset of symptoms. Five of the patients had detectable antibodies by the 3rd week into their illness and there was evidence of seroconversion in 4 patients. The IIFA method was marginally more sensitive compared to the ELISA assay, however the IIFA IgM test was not useful in the early phase of the illness with poor sensitivity. Conclusions: Existing diagnostic assays for SARS-CoV can detect antibodies in patients who were diagnosed with COVID-19. These assays maybe be utilized as an interim measure in epidemiological investigations for contact tracing and to determine the extent of community spread of this new emerging virus pending the availability of specific serology tests for SARS-CoV-2.
has issue date	2020-03-23(xsd:dateTime)
bibo:doi	10.1101/2020.03.17.20034454
has license	medrxiv
sha1sum (hex)	bc4410fe641e692dddea2a54aa2732c3032bdae2
schema:url	https://doi.org/10.1101/2020.03.17.20034454
resource representing a document's title	Cross-reaction of sera from COVID-19 patients with SARS-CoV assays.
resource representing a document's body	covid:bc4410fe641e692dddea2a54aa2732c3032bdae2#body_text
is schema:about of	named entity 'SARS-CoV' named entity 'COVID' named entity 'SARS-CoV' named entity 'probability' named entity 'SARS' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software